View ValuationEntropy Neurodynamics 将来の成長Future 基準チェック /06現在、 Entropy Neurodynamicsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長42.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Dec 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m). Market cap is less than US$100m (AU$54.7m market cap, or US$35.8m).New Risk • Nov 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$7.9m free cash flow). Minor Risks Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m). Market cap is less than US$100m (AU$52.0m market cap, or US$33.8m).お知らせ • Nov 05Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 165,588,236 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,823,528 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Transaction Features: Subsequent Direct Listingお知らせ • Sep 16Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025. Location: suite 1.01 117 camberwell road, hawthorn east vic 3123, AustraliaNew Risk • Jul 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$1.3m revenue, or US$865k). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$46.0m market cap, or US$30.0m).お知らせ • Mar 31Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Nov 06Tryptamine Therapeutics Limited Announces Peter Molloy to Resign as Non-Executive Director from the Board, Effective November 8, 2024Tryptamine Therapeutics Limited announced that Non-Executive Director Mr. Peter Molloy will resign from the Board of Directors. Mr. Molloy's resignation follows the Company's strategic placement to raise $6 million to fast track its TRP-8803 (IV-infused psilocin) clinical trial strategy, which has also led to the pending appointment of Dr. Daniel Tillett as a Non-Executive Director. Mr. Molloy has been a member of the Company since September 2020 and was influential in Tryp's growth trajectory. He provided valued support in the Company's transition to the Australian Securities Exchange. Dr. Tillett's appointment and Mr. Molloy's resignation will occur after the conclusion of the Company Annual General Meeting, scheduled for November 8, 2024.お知らせ • Nov 01Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct ListingBoard Change • Oct 09High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director P. Jull is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.New Risk • Sep 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.5m free cash flow). Negative equity (-CA$5.9m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$26.4m market cap, or US$18.0m).お知らせ • Sep 06Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024.お知らせ • Sep 03Tryptamine Therapeutics Limited Announces Chief Financial Officer ChangesTryptamine Therapeutics Limited advised that Mr. Hamish George has been appointed Chief Financial Officer (‘CFO’), effective 1 September 2024. As part of the appointment, previous CFO Mr. Jim O'Neill has resigned. Mr. George is a Director at Bio101 Financial Advisory (‘Bio101’). He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr. George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. The Company announced that Mr. Jim O'Neill provided wide-ranging support to advance the transition of roles to Mr. George during August 2024, enabling him to be fully engaged as CFO from 1 September 2024.New Risk • Aug 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.5m free cash flow). Negative equity (-CA$5.9m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$32.2m market cap, or US$21.5m).Recent Insider Transactions • Jun 04MD, CEO & Executive Director recently bought AU$62k worth of stockOn the 30th of May, Jason Carroll bought around 3m shares on-market at roughly AU$0.025 per share. This transaction amounted to 8.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jason's only on-market trade for the last 12 months. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Entropy Neurodynamics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ASX:ENP - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252-5-5-5N/A9/30/20252-5-7-7N/A6/30/20252-5-8-8N/A6/30/20241-7-7-7N/A2/29/2024N/A-5-5-5N/A11/30/2023N/A-5-4-4N/A8/31/2023N/A-6-4-4N/A5/31/2023N/A-7-4-4N/A2/28/2023N/A-6-4-4N/A11/30/2022N/A-7-6-6N/A8/31/2022N/A-8-7-6N/A5/31/2022N/A-9-7-7N/A2/28/2022N/A-11-8-8N/A11/30/2021N/A-12-7-7N/A8/31/2021N/A-9-6-5N/A5/31/2021N/A-6-3-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ENPの予測収益成長が 貯蓄率 ( 3.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ENPの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ENPの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ENPの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ENPの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ENPの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/22 23:10終値2026/07/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Entropy Neurodynamics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Michael HigginsLadenburg Thalmann & Company
New Risk • Dec 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m). Market cap is less than US$100m (AU$54.7m market cap, or US$35.8m).
New Risk • Nov 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$7.9m free cash flow). Minor Risks Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m). Market cap is less than US$100m (AU$52.0m market cap, or US$33.8m).
お知らせ • Nov 05Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 165,588,236 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,823,528 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 16Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025. Location: suite 1.01 117 camberwell road, hawthorn east vic 3123, Australia
New Risk • Jul 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$1.3m revenue, or US$865k). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$46.0m market cap, or US$30.0m).
お知らせ • Mar 31Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Nov 06Tryptamine Therapeutics Limited Announces Peter Molloy to Resign as Non-Executive Director from the Board, Effective November 8, 2024Tryptamine Therapeutics Limited announced that Non-Executive Director Mr. Peter Molloy will resign from the Board of Directors. Mr. Molloy's resignation follows the Company's strategic placement to raise $6 million to fast track its TRP-8803 (IV-infused psilocin) clinical trial strategy, which has also led to the pending appointment of Dr. Daniel Tillett as a Non-Executive Director. Mr. Molloy has been a member of the Company since September 2020 and was influential in Tryp's growth trajectory. He provided valued support in the Company's transition to the Australian Securities Exchange. Dr. Tillett's appointment and Mr. Molloy's resignation will occur after the conclusion of the Company Annual General Meeting, scheduled for November 8, 2024.
お知らせ • Nov 01Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Board Change • Oct 09High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director P. Jull is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
New Risk • Sep 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.5m free cash flow). Negative equity (-CA$5.9m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$26.4m market cap, or US$18.0m).
お知らせ • Sep 06Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024.
お知らせ • Sep 03Tryptamine Therapeutics Limited Announces Chief Financial Officer ChangesTryptamine Therapeutics Limited advised that Mr. Hamish George has been appointed Chief Financial Officer (‘CFO’), effective 1 September 2024. As part of the appointment, previous CFO Mr. Jim O'Neill has resigned. Mr. George is a Director at Bio101 Financial Advisory (‘Bio101’). He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr. George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. The Company announced that Mr. Jim O'Neill provided wide-ranging support to advance the transition of roles to Mr. George during August 2024, enabling him to be fully engaged as CFO from 1 September 2024.
New Risk • Aug 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.5m free cash flow). Negative equity (-CA$5.9m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$32.2m market cap, or US$21.5m).
Recent Insider Transactions • Jun 04MD, CEO & Executive Director recently bought AU$62k worth of stockOn the 30th of May, Jason Carroll bought around 3m shares on-market at roughly AU$0.025 per share. This transaction amounted to 8.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jason's only on-market trade for the last 12 months.